Aqemia, a startup in France founded by Maximilien Levesque and Emmanuelle Martiano, is utilizing AI and physics to expedite drug development, particularly for cancers of the head, neck, and chest. The company aims to reduce the traditional 10-15 year timeline for drug creation by using AI to identify effective molecules based on physical principles rather than solely on large datasets. Aqemia has partnered with major pharmaceutical companies and is progressing towards clinical trials for new drugs by late 2026 or early 2027. Teljes cikk (Euronews.com)